Cargando…

Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nadinskaia, Maria, Maevskaya, Marina, Ivashkin, Vladimir, Kodzoeva, Khava, Pirogova, Irina, Chesnokov, Evgeny, Nersesov, Alexander, Kaibullayeva, Jamilya, Konysbekova, Akzhan, Raissova, Aigul, Khamrabaeva, Feruza, Zueva, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Clinical Trials Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968130/ https://www.ncbi.nlm.nih.gov/pubmed/33776366 http://dx.doi.org/10.3748/wjg.v27.i10.959

Ejemplares similares

Rapidly Progressive Portal Cavernoma Cholangiopathy in a Patient With Infeasible Decompressive Shunt Surgery
por: Nadinskaia, Maria Yu, et al.
Publicado: (2023)

The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
por: Elhini, Sahar H., et al.
Publicado: (2022)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
por: Ulasoglu, Celal, et al.
Publicado: (2021)

Is Vitamin E or Ursodeoxycholic Acid a Valid Treatment Option for Nonalcoholic Fatty Liver Disease in 2016?
por: Beaton, Melanie D., et al.
Publicado: (2016)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

Nonalcoholic Fatty Liver Disease: Noninvasive Methods of Diagnosing Hepatic Steatosis
por: AlShaalan, Rasha, et al.
Publicado: (2015)

Herbicide Widespread: The Effects of Pethoxamid on Nonalcoholic Fatty Liver Steatosis In Vitro
por: Pirozzi, Anna Virginia Adriana, et al.
Publicado: (2020)

Hepatic Steatosis in Infancy: The Beginning of Pediatric Nonalcoholic Fatty Liver Disease?
por: McNelis, Kera, et al.
Publicado: (2021)

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
por: Ahn, Sang Bong
Publicado: (2023)

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
por: Lee, Hyo Young, et al.
Publicado: (2019)

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
por: Lee, Na Young, et al.
Publicado: (2021)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice
por: Yuan, Youwen, et al.
Publicado: (2022)

Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study
por: Kaibullayeva, Jamilya, et al.
Publicado: (2020)

Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats
por: Fukunishi, Shinya, et al.
Publicado: (2014)

Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease
por: Pirmoazen, Amir M., et al.
Publicado: (2020)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment
por: Shao, Congxiang, et al.
Publicado: (2022)

Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease
por: Jo, Ik Hyun, et al.
Publicado: (2023)

Effect of skin–capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease
por: Kimura, Syunichiro, et al.
Publicado: (2021)

Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis
por: Maslennikov, Roman, et al.
Publicado: (2023)

Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan
por: Nersesov, Alexander, et al.
Publicado: (2021)

Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis
por: Mendel, Itzhak, et al.
Publicado: (2016)

Cyanotoxins Increase Cytotoxicity and Promote Nonalcoholic Fatty Liver Disease Progression by Enhancing Cell Steatosis
por: Niture, Suryakant, et al.
Publicado: (2023)

The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy
por: Mikolasevic, Ivana, et al.
Publicado: (2022)

Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
por: Zenovia, Sebastian, et al.
Publicado: (2021)

Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease
por: Luukkonen, Panu K., et al.
Publicado: (2020)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease
por: Behari, Jaideep, et al.
Publicado: (2021)

Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults
por: Sui, Guoyuan, et al.
Publicado: (2021)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2021)

Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients
por: Wang, Qingling, et al.
Publicado: (2022)

Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease
por: Kosasih, Sumitro, et al.
Publicado: (2018)

Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity
por: Buryova, Halka, et al.
Publicado: (2013)

Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review
por: Reardon, Jillian, et al.
Publicado: (2016)

Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
por: Tamai, Hideyuki, et al.
Publicado: (2023)

Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease
por: Li, Yanyan, et al.
Publicado: (2023)

Hepatorenal Index by B‐Mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcohol‐Related and Nonalcoholic Fatty Liver Disease
por: Kjaergaard, Maria, et al.
Publicado: (2022)

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease
por: Ahn, Jem Ma, et al.
Publicado: (2016)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
por: Hu, Ying-Bin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ea15ji3r7r576fj0edrh3heh29